Kurve Therapeutics | What We Do

Kurve Therapeutics’ patented Controlled Particle Dispersion (CPD)® technology significantly enhances the efficacy and dosage control of drug formulations by bypassing the blood-brain barrier.

Small as well as large, complex molecules have shown promise in treating neurodegenerative diseases, but other non-surgical technology — oral or intravenous — have seen little success in penetrating the blood-brain barrier. We have the answer to distributing medication to this targeted location through our technology’s enhanced reach into the brain.

Product Overview Video

The Controlled Particle Dispersion® device creates a precisely-controlled turbulent flow which allows medications to pass through the curved surfaces inside the nose and up to the olfactory mucosa at the top of the nasal cavity. This nose-to-brain region is where nerves penetrate to convey smell signals to the brain, but has historically been nearly impossible to deliver complex molecules to without the use of surgical methods.

Global Needs

Kurve Technology Global Needs 1

Roughly one in six people — over one billion people — suffer from neurological disorders globally.

Kurve Technology Global Needs 2

Family members and friends provided nearly $257 billion in unpaid care to people living with Alzheimer’s and other dementias in 2020. Not counting family care, the total national cost of caring for people living with Alzheimer’s and other dementias was projected to reach $355 billion in 2021.

Kurve Technology Global Needs 3

Every 3 seconds, someone in the world develops dementia.

Kurve Technology Global Needs 4

350,000 new cases of early-onset dementia occur globally every year. The number of Americans with the disease will increase to a projected 7.1 million people by 2025, an increase of nearly 22%.

Kurve Technology Global Needs 5

The most common cause of dementia is Alzheimer’s disease, which accounts for roughly 60% to 80% of cases in the 55 million people living with dementia worldwide. This number is estimated to double every 20 years.

Kurve Technology Global Needs 6

Parkinson’s disease is the second most common neurodegenerative disorder, with an estimated 9.4 million people suffering from the disease globally. Parkinson’s related surgery can cost a patient up to $100,000.

Kurve Technology Global Needs 7

There are currently 2.8 million people diagnosed with Multiple Sclerosis, with nearly one million in the US alone.

Kurve Technology Global Needs 8

There is strong evidence that diabetes increases the risk of cognitive impairment and dementia; people with diabetes have a 50–100% higher chance of being affected by dementia; this disease accelerates the aging of the brain by five years. As of 2021, there are 537 million people living with diabetes worldwide, with about 10.5% of the US population — 34.2 million — living with the disease. By 2045, the global number is expected to grow to 783 million diabetics.

Features and Benefits

Kurve Technology Features and Benefits Increases treatment efficacy

Increases treatment efficacy through better access to targeted organs and/or tissues

Kurve Technology Features and Benefits Reduce side-effects

Reduces systemic side-effects by ensuring less medication reaches non-targeted areas

Enhances the opportunity for bioavailability: delivers droplets that rest below the zone of ciliated action (the clearance mechanism of the nasal mucosa), allowing for longer residence time, which improves transferability and accelerates onset of action

Greater dosage precision through programmable electronic circuitry and advanced mechanics, which deliver the intended, precise amount of medication while enhancing concentration in the desired area within the nasal cavity

Exceptional patient compliance: Kurve’s CPD® device is non-invasive, simplified, and features user-friendly modes of administration, all of which encourage patient compliance and use while minimizing application errors

Odorless, tasteless, and painless delivery of medication

Kurve Technology Features and Benefits Device

Device is pocket-size, lightweight, portable, and battery-powered

Kurve Technology Features and Benefits Medication administration made easy

Medication administration made easy: a typical dosage is taken twice daily for about 15 seconds each time

Target Diseases

Kurve Therapeutics’ Controlled Particle Dispersion® technology can help enhance treatment for a variety of neurodegenerative diseases with proven, disease-modifying clinical success. A full list of studies is available upon request.

Alzheimer's Disease

Alzheimer’s is the only top-10 cause of death in the United States without an approved, disease-modifying drug. With an estimated six million US patients, it is the sixth-leading cause of death in the US, and the fifth-leading cause of death among those age 65 and older in the US.

It is also estimated to be the most expensive disease in the nation. There is opportunity to grow the market significantly with an effectively-delivered, disease-modifying drug.

No new drug has been approved by the FDA for Alzheimer’s disease since 2003 and there are no approved DMTs for AD, despite many long and expensive trials.

Approved treatments address only symptoms; the currently approved treatments are only effective for a short time — 3–6 months — after which, the patients continue to decline and eventually pass, typically from their disease. The current treatment options slow the progression of the illness for a limited time, until the body adjusts to the medication, eventually rendering the drug ineffective. They also require dosage increases which have deteriorative effects on the body. These treatments do not modify the disease.

Kurve technology has been studied in Alzheimer’s patients through five double-blind, placebo-controlled Phase II studies.

Parkinson's Disease

Kurve Technology Target Diseases Parkinson's Disease

Parkinson’s affects about 930,000 US patients, with 2030 prevalence forecast to grow to 1.2 million patients. While some patients’ symptoms can be treated effectively for years, there are currently no approved drugs that treat the underlying neurodegenerative process.

Global revenues for Parkinson’s drugs were $4.5 billion in 2018. There is substantial opportunity to enlarge this market with a therapy yielding the disease-modifying experiences seen in some Kurve patients.

Mild Cognitive Impairment (MCI)

Mild Cognitive Impairment

Mild Cognitive Impairment (MCI) is an early phase in between normal aging-related cognition issues and dementia. While it is not as debilitating as dementia, it may increase an individual’s risk of later developing a form of dementia, such as Alzheimer’s disease. MCI typically includes a decline in verbal fluency, short-term memory, attention span, and judgment.

MCI affects 10-20% of people over the age of 65, and is shown to increase as an individual ages. Those diagnosed with Mild Cognitive Impairment have about 20% probability of developing dementia within their third year of diagnosis.

There are currently no approved treatments or drugs to treat MCI. While some patients are prescribed medications used to treat Alzheimer’s, the efficacy of these treatments have been mostly ineffective and do not help prevent the onset of dementia.

Kurve Therapeutics’ technology has been studied in MCI through 18-month long clinical trials.

Lewy Body Dementia (LBD)

Kurve Technology Target Diseases Lewy Body Dementia

LBD affects roughly 1.4 million individuals — and their families — in the United States. It is the third-most-common dementia in the US after Alzheimer’s and vascular dementia.

Global LBD drug revenues were $3.5 billion in 2018.

There are currently no approved treatments demonstrated to slow or stop the brain cell damage caused by Lewy Body Dementia. Several LBD patients have benefited significantly from Kurve treatments, however. Patient case reports are pending.

Amyotrophic Lateral Sclerosis (ALS)

Kurve Technology Target Diseases Amyotrophic Lateral Sclerosis

ALS is a rare disease, with about 16,000 patients suffering from it in the US.

There are currently only two drugs approved for the treatment of ALS:

  • Sanofi’s Rilutek (riluzole) and Mitsubishi Tanabe’s Radicava (edaravone).
  • The drugs were special cases in terms of FDA approval; they did not meet the standard regulatory requirements for approval, but due to the increase in survival of patients, they were granted approval.

Drug sales for ALS in 2017 were collectively about $200 million in the US, Japan and major European markets (Germany, France, UK, Italy and Spain).

Contact Us

Title/Role